JWA
NKTR icon

JFS Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

JFS Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Hold
0
– – – 1870
2022
Q1 		– Sell
-2
Closed -$296 – 1913
2021
Q4 		$0 Buy
+2
New +$434 ﹤0.01% 1825

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

JFS Wealth Advisors's NKTR Position: Q2 2022 in Review

JFS Wealth Advisors held its Nektar Therapeutics (NKTR) position steady in Q2 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1870.

JFS Wealth Advisors first reported a position in NKTR in Q4 2021 and has held it in 1 quarter since. The position peaked at $0 in Q4 2021. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

  • JFS Wealth Advisors held 0 shares of Nektar Therapeutics worth $0 as of Q2 2022.
  • JFS Wealth Advisors left its Nektar Therapeutics share count unchanged in Q2 2022.
  • Nektar Therapeutics made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2022, its #1870 holding.
  • JFS Wealth Advisors first reported a position in Nektar Therapeutics in Q4 2021 and has held it in 1 quarter since.
  • JFS Wealth Advisors's Nektar Therapeutics position peaked at $0 in Q4 2021.
  • 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on JFS Wealth Advisors's 13F filing for Q2 2022, filed 2 Aug 2022.